euro adhoc: Sartorius AG
quarterly or semiannual financial statement
Figures
for the First Quarter of 2008
Sales revenue rose 3.8% (currency-adjusted: up 7.7%) | Currency-adjusted order
intake up 3.4% | EBITA at EUR12.2 million up from the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
22.04.2008
To ensure the best possible comparability, the first-quarter figures of 2007 are shown on a pro forma basis and adjusted for extraordinary expenses.
Within the first three months of 2008, the Sartorius Group increased sales revenue by 3.8% to EUR149.2 million (Q1 2007: EUR143.6 mn). Currency-adjusted consolidated sales revenue climbed 7.7%. The Biotechnology Division's sales revenue rose 5.4% (currency-adjusted: +9.5%) to EUR90.6 (Q1 2007: EUR85.9 mn). Sales revenue for the Mechatronics Division grew 1.5% (currency-adjusted: +5.1%) to EUR58.6 million (Q1 2007: EUR57.7 mn).
At EUR162.5 million, order intake was higher than sales revenue and thus at the high level of the year-earlier quarter (EUR162.9 mn). On the basis of constant currencies, order intake rose 3.4%. The difference between sales revenue and order intake essentially resulted from the fluctuations in the equipment business of the Biotechnology Division. The Division's order intake was EUR97.6 million (Q1 2007: EUR99.1 million), which corresponds to a decline of 1.5% or a currency-adjusted increase of 2.2%. The value of orders for the Mechatronics Division rose 1.8% or by a currency-adjusted rate of 5.3%.
First-quarter operating earnings (earnings before interest, taxes and amortization = EBITA) increased from EUR11.8 million to EUR12.2 million. At 8.2%, the EBITA margin remained unchanged compared to the year-earlier figure. If the EBITA margin had been calculated based on the previous year's exchange rates, it would have increased to more than 9%. EBITA for the Biotechnology Division rose from EUR8.4 million to EUR9.1; for the Mechatronics Division, EBITA at EUR3.1 million was below the year-earlier figure of EUR3.4 million. Net profit after minority interest was EUR3.2 million (Q1 2007: EUR3.5 million); earnings per share (excluding the two non-cash items of amortization and interest on share price warrants granted) were EUR0.25 (Q1 2007: EUR0.26).
For the full fiscal year of 2008, the Sartorius Group is continuing to aim at achieving sales revenue growth of more than 9% in constant currencies. Based on this anticipated sales revenue and on an average exchange rate of 1.40 USD/EUR, the Group is planning to increase the EBITA margin to approx. 12%.
|EUR in millions |Q1 2008 |Q1 2007 |Change | |(unless otherwise specified) | |pro forma |in % | | | | | | |Sartorius Group | | | | |Sales revenue |149.2 |143.6 |+3.8 (+7.7)| |Order intake |162.5 |162.9 |-0.2 (+3.4)| |EBITA 1) |12.2 |11.8 |+3.7 | |Net profit for the period 1)2) |4.2 |4.4 |-2.9 | |Earnings per share 1)2) in EUR |0.25 |0.26 |-2.9 | | | | | | |Biotechnology Division | | | | |Sales revenue |90.6 |85.9 |+5.4 (+9.5)| |Order intake |97.6 |99.1 |-1.5 (+2.2)| |EBITA 1) |9.1 |8.4 |+8.5 | | | | | | |Mechatronics Division | | | | |Sales revenue |58.6 |57.7 |+1.5 (+5.1)| |Order intake |64.9 |63.8 |+1.8 (+5.3)| |EBITA 1) |3.1 |3.4 |-7.9 |
in parentheses: currency-adjusted 1) for 2007 underlying 2) excluding non-cash amortization and, for 2008, additionally excluding non-cash interest expenses for share price warrants
Dr. Joachim Kreuzburg, CEO of Sartorius, will discuss the quarterly results for Sartorius with analysts and investors in a teleconference at 4:30 p.m. CET following today's Annual Shareholder Meeting. You may dial into this teleconference starting at 4:15 p.m. CET at the following numbers:
Germany: +49 (0)69 5007 1316; France: +33 (0)1 70 99 42 99; UK: +44 (0)20 7806 1968; USA: +1 718 354 1387.
The dial-in code is 3601455;
to view the webcast, log onto www.livemeeting.com/cc/premconfeurope/j oin?id=3601455&role=attend&pw=pw7076
end of announcement euro adhoc
Further inquiry note:
Andreas Wiederhold
Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com
Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade